Potential for immunotherapy: PEM as a target antigen

  • J. Taylor-Papadimitriou
  • N. Peat
  • J. Burchell
  • P. Beverley
  • M. Smith


In looking for novel therapies for the effective treatment of ovarian cancer, particularly as an adjuvant to surgery, immunotherapy is an option which is ready to be explored. Two reasons why this option may now be a realistic one are that potential target antigens are being identified and considerable advances have been made in understanding the underlying mechanisms involved in tumour rejection and in antigen presentation and recognition by the various components of the immune system. The possibility of extending immunotherapy to prevention (at least for prevention of recurrence of the disease) is also a real one since active specific immunotherapy (ASI) appears to be unaccompanied by obvious serious side effects.


Ovarian Cancer Ovarian Cancer Patient Ovarian Cancer Cell Line Tumour Rejection MUC1 Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hung, M.C., Zhang, X., Yen, D.H. et al. (1992) Aberrant expression of the c-erbB-2/ neu protooncogene in ovarian cancer. Cancer Lγett., 61, 95–103.PubMedCrossRefGoogle Scholar
  2. 2.
    Campbell, I.G., Jones, T.A., Foulkes, W.D. et al. (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res., 51, 5329–38.PubMedGoogle Scholar
  3. 3.
    Mazars, R., Pujol, P., Maudelonde, T. et al. (1991) p53 mutations in ovarian cancer: a late event? Oncogene, 6, 1685–90.PubMedGoogle Scholar
  4. 4.
    Lamb, P. and Crawford, L. (1986) Characterization of the human p53 gene. Cancer Res., 6, 1379–85.Google Scholar
  5. 5.
    Van der Bruggen, P., Traversari, C., Chomez, P. et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.Science, 254,1643–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Hird, V., Snook, D., Dhokia, B. et al. (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68, 403–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Schwartz, R.H. (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Linsley, P.S., Brady, W., Grosmaire, L. et al. (1992) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, J.Exp. Med., 173, 721–30.Google Scholar
  9. 9.
    Chen, L., Ashe, S., Brady, W.A. et al. (1992) Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Browning, M.J. and Bodmer, W.F. (1992) MHC antigens and cancer: implications for T-cell surveillance. Curr. Opinion Immunol 4,613–18.CrossRefGoogle Scholar
  11. 11.
    Burchell, J. and Taylor-Papadimitriou, J. (1989) Antibodies to human milk fat globule molecules. Cancer Invest., 17, 53–61.CrossRefGoogle Scholar
  12. 12.
    Gendler, S.J., Lancaster, C.A., Taylor-Papadimitriou, J. et al. (1990) Molecular cloning and expression of the human tumourassociated polymorphic epithelial mucin. J. Biol Chem., 265, 15286–93.PubMedGoogle Scholar
  13. 13.
    Ligtenberg, M., Vos, H., Gennissen, A. et al. (1990) Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. Biol Chem., 265, 5573–8.PubMedGoogle Scholar
  14. 14.
    Wreschner, D.H., Hareuveni, M., Tsarfaty, I. et al. (1990) Human epithelial tumor antigen cDNA sequences. Eur. J. Biochem., 189,463–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Siddiqui, J., Abe, M., Hayes, D. et al. (1988) Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma- associated antigen. Proc. Natl Acad. Sci. USA, 85,2320–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Lan, M., Batra, S., Qi, W-N. et al. (1990) Cloning and sequencing of a human pancreatic tumour mucin cDNA. J. Biol. Chem., 265, 15294–9.PubMedGoogle Scholar
  17. 17.
    Burchell, J., Gendler, S.J., Taylor-Papadimitriou, J. et al. (1987) Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer. Res., 47, 5476–82.PubMedGoogle Scholar
  18. 18.
    Girling, J.R., Bartkova, J., Burchell, J. et al. (1989) A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer, 43, 1072–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Gunn, J.R., Byrd, J., Hicks, J. et al. (1989) Molecular cloning of human intestinal mucin cDNAs. J. Biol Chem., 264, 6480–7.Google Scholar
  20. 20.
    Gum, J.R., Hicks, J., Swallow, D. et al. (1990) Molecular cloning of cDNAs derived from a novel human intestinal mucin gene.Biochem. Biophys. Res. Commun., 171,407–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Porchet, N., van Cong, N., Dufosse, J. et al. (1991) Molecular cloning and chromosomal localization of a novel human tracheobronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem. Biophys. Res. Commun., 175,414–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Langdon, S.P., Lawrie, S.S., Hay, F.G. et al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res., 48, 6166–72.PubMedGoogle Scholar
  23. 23.
    Burchell, J., Taylor-Papadimitriou, J., Boshell, M. et al. (1989) A short sequence within the amino acid tandem repeat of a cancer associated mucin contains immunodominant epitopes. Int. J. Cancer, 44,691–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Taylor-Papadimitriou, J. (1991) Report on the First International Workshop on Carcinomaassociated Mucins. Int. J. Cancer, 49, 1–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Lancaster, C., Peat, N., Duhig, T. et al. (1990) Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem. Biophys. Res. Commun., 173, 1019–29.PubMedCrossRefGoogle Scholar
  26. 26.
    Hanish, F.G., Uhlenbruck, G., Peter-Katalinic, J. et al. (1989) Structure of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyl-lactosamine backbones with Galiβ(l-4) GlcNAciβ(l-6) repeating units. J. Biol Chem., 265, 872–83.Google Scholar
  27. 27.
    Hull, S.R., Bright, A., Carraway, K.L. et al. (1989) Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.Cancer Commun., 1, 261–7.PubMedGoogle Scholar
  28. 28.
    Van Daam, P.A., Lowe, D.G., Watson, J.V. et al. (1991) Multiparameter flow cytometric quantitation of the expression of the tumor- associated antigen SM3 in normal and neoplastic ovarian tissues. Cancer, 68,169–77.CrossRefGoogle Scholar
  29. 29.
    Granowska, M, Mather, S.J., Jobling, T. et al. (1990) Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int. J. Biol. Markers, 5, 89–96.PubMedGoogle Scholar
  30. 30.
    Barnd, D.L., Lan, M.S., Metzgar, R.S. et al. (1989) Specific, major histocompatibilty complex-unrestricted recognition of tumor- associated mucins by human cytotoxic T cells.Proc. Natl. Acad. Sci. USA, 86, 7159–64.PubMedCrossRefGoogle Scholar
  31. 31.
    Jerome, K.R., Barnd, K.L. Bendt, K.M. et al. (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.Cancer Res., 51, 2908–16.PubMedGoogle Scholar
  32. 32.
    Rughetti, A., Turchi, V., Apolonj Ghetti, C. et al. (1993) Human B cell immune response against the polymorphic epithelial mucin (PEM). Cancer Res., 53, 2457–90.PubMedGoogle Scholar
  33. 33.
    Fung, P.Y.S., Made], M., Koganty, R. et al. (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50, 4308.PubMedGoogle Scholar
  34. 34.
    Singhal, A., Fohn, M. and Hakomori, S. (1991)Induction of α-N-acetylgalactosamine- O-serine/threonine (Tn) antigen-mediated. cellular immune response for active immunotherapy in mice. Cancer Res., 51, 1406–14.PubMedGoogle Scholar
  35. 35.
    MacLean, G.D., Bowen-Yacyshyn, M.B., Samuel, J. et al. (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen- 43. Friedenreich) determinant using a synthetic carbohydrate antigen, J.Immunother., 11, 292–305.PubMedCrossRefGoogle Scholar
  36. 36.
    Lalani, E.N., Berdichevsky, F., Boshell, M. et al. (1991) Expression of the gene coding for a human mucin in mouse mammary tumour cells can affect their tumorigenicity. J. Biol Chem., 266, 15420–6.PubMedGoogle Scholar
  37. 37.
    Ding, L., Lalani, E.N., Reddish, M. et al. (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCl mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUCl gene. J. Cancer Immunol Immunother., 36, 9–17.CrossRefGoogle Scholar
  38. 38.
    Vos, H.L., Devarayalu, Y., de Vries, Y. and Bornstein, P. (1992) Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. J. Biol Chem., 267, 12192–6.PubMedGoogle Scholar
  39. 39.
    Peat, N., Gendler, S.J., Lalani, E.N., (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUCl) in transgenic mice. Cancer Res., 52, 1954–60.PubMedGoogle Scholar
  40. 40.
    Kovarik, A., Peat, N., Wilson, D. et al. (1993) Analysis of the tissue specific promoter of the MUCl gene. J.Biol Chem., 268,9917–26.PubMedGoogle Scholar
  41. 41.
    Aldovini, A. and Young, R.A. (1991) Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature, 35, 1479–82.Google Scholar
  42. 42.
    Dranoff, G., Jaffee, E., Lazenby, A. et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte- macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90, 3539–43.PubMedCrossRefGoogle Scholar
  43. 43.
    Tao, M.H. and Levy, R. (1993) A novel vaccine for B-cell lymphoma: idiotype/granulocyte- macrophage colony-stimulating factor fusion protein. Nature, 362, 755–8.PubMedCrossRefGoogle Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • J. Taylor-Papadimitriou
  • N. Peat
  • J. Burchell
  • P. Beverley
  • M. Smith

There are no affiliations available

Personalised recommendations